ABT
Abbott Laboratories
Stock
$96.69−2.14 (−2.17%)Close Oct 1, 2026
Income statement
| Line | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $46.6B | $44.3B | $42.0B | $40.1B | $43.7B | $43.1B | $34.6B | $31.9B | $30.6B | $27.4B | $20.9B | $20.4B | $20.2B | $19.7B | $19.1B | $21.4B | $35.2B | $30.8B | $29.5B | $25.9B |
| Cost of revenue | $20.2B | $19.3B | $18.7B | $18.0B | $19.1B | $18.5B | $15.0B | $13.2B | $12.7B | $12.4B | $9.1B | $8.7B | $9.2B | $9.2B | $8.9B | $10.0B | $14.7B | $13.2B | $12.6B | $11.4B |
| Gross profit | $26.4B | $25.0B | $23.2B | $22.1B | $24.5B | $24.5B | $19.6B | $18.7B | $17.9B | $15.0B | $11.8B | $11.7B | $11.0B | $10.5B | $10.2B | $11.4B | $20.5B | $17.6B | $16.9B | $14.5B |
| R&D | $3.2B | $2.9B | $2.8B | $2.7B | $2.9B | $2.7B | $2.4B | $2.4B | $2.3B | $2.3B | $1.4B | $1.4B | $1.3B | $1.4B | $1.5B | $1.5B | $3.7B | $2.7B | $2.7B | $2.5B |
| SG&A | $13.9B | $12.3B | $11.7B | $10.9B | $11.2B | $11.3B | $9.7B | $9.8B | $9.7B | $9.2B | $6.7B | $6.8B | $6.5B | $6.4B | $6.7B | $7.4B | $10.4B | $8.4B | $8.4B | $7.4B |
| Other operating expenses | $1.9B | $1.7B | $1.9B | $2.0B | $2.0B | $2.0B | $2.1B | $1.9B | $2.2B | $2.0B | $550M | $601M | $555M | $588M | $595M | $884M | $313M | $170M | $97M | — |
| Operating income | $7.3B | $8.1B | $6.8B | $6.5B | $8.4B | $8.4B | $5.4B | $4.5B | $3.7B | $1.6B | $3.0B | $2.9B | $2.6B | $2.1B | $1.4B | $1.6B | $6.1B | $6.2B | $5.7B | $4.6B |
| Non-operating income | $165M | $413M | $188M | $186M | −$56M | −$214M | −$389M | −$455M | −$777M | $667M | −$1.6B | $316M | −$81M | −$92M | −$1.6B | −$393M | −$375M | $958M | — | — |
| Pretax income | $7.5B | $8.5B | $7.0B | $6.7B | $8.3B | $8.2B | $5.0B | $4.1B | $2.9B | $2.2B | $1.4B | $3.2B | $2.5B | $2.0B | −$220M | $1.2B | $5.7B | $7.2B | — | — |
| Taxes | $2.1B | $1.9B | −$6.4B | $941M | $1.4B | $1.1B | $473M | $390M | $505M | $1.8B | $13M | −$1.2B | $234M | −$535M | −$6.2B | −$3.5B | $1.1B | $1.4B | — | — |
| Net income | $5.4B | $6.5B | $13.4B | $5.7B | $6.9B | $7.1B | $4.5B | $3.7B | $2.4B | $477M | $1.4B | $4.4B | $2.3B | $2.6B | $6.0B | $4.7B | $4.6B | $5.7B | $4.9B | $3.6B |
| Diluted EPS | $3.11 | $3.72 | $7.64 | $3.26 | $3.91 | $3.94 | $2.50 | $2.06 | $1.33 | $0.27 | $0.94 | $2.92 | $1.49 | $1.62 | $3.72 | $3.01 | $2.96 | $3.69 | $3.12 | $2.31 |
| Diluted shares | — | 1.75B | 1.75B | 1.75B | 1.76B | 1.79B | 1.79B | 1.78B | 1.77B | 1.75B | 1.48B | 1.51B | 1.53B | 1.57B | 1.59B | 1.57B | 1.56B | 1.56B | 1.56B | 1.56B |
| Revenue growth | — | +5.7% | +4.6% | −8.1% | +1.3% | +24.5% | +8.5% | +4.3% | +11.6% | +31.3% | +2.2% | +0.8% | +3.0% | +3.2% | −11.0% | −39.1% | +14.3% | +4.2% | +13.9% | — |
| Gross margin | 56.6% | 56.4% | 55.4% | 55.2% | 56.1% | 57.0% | 56.6% | 58.5% | 58.4% | 54.7% | 56.4% | 57.1% | 54.5% | 53.2% | 53.3% | 53.2% | 58.3% | 57.1% | 57.3% | 55.9% |
| Operating margin | 15.8% | 18.2% | 16.3% | 16.2% | 19.2% | 19.6% | 15.5% | 14.2% | 11.9% | 5.7% | 14.5% | 14.1% | 12.8% | 10.9% | 7.1% | 7.6% | 17.3% | 20.3% | 19.3% | 17.7% |
| Net margin | 11.6% | 14.7% | 31.9% | 14.3% | 15.9% | 16.4% | 13.0% | 11.6% | 7.7% | 1.7% | 6.7% | 21.7% | 11.3% | 13.1% | 31.3% | 22.1% | 13.2% | 18.7% | 16.5% | 13.9% |
Cost of revenue, other operating expenses, non-operating income and taxes are the differences between the lines reported around them.